Add to ORKGAnakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes
Pharmacokinetic properties and safety profile of a drug are likely influenced by the disease state o...
Anakinra is a biologic response modifier that competitively antagonises the biologic effects of inte...
The use of NSAIDs for arthritis differs in children from adults in their indications, uses and pharm...
International audienceBACKGROUND: Anakinra pharmacokinetics and pharmacodynamics were investigated i...
Anakinra pharmacokinetics and pharmacodynamics were investigated in children and adolescents treated...
We have evaluated anakinra drug retention rate and predictive factors of drug survival in a cohort o...
To assess the efficacy of the interleukin 1 receptor antagonist anakinra in systemic-onset juvenile ...
Interleukin 1 (IL-1), a central mediator of innate immunity, is considered a master cytokine of loca...
The pharmacokinetics and pharmacodynamic (PD) properties of a monoclonal antibody, canakinumab, in p...
Objectives To assess the effi cacy of the interleukin 1 receptor antagonist anakinra in systemic-ons...
Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idio...
Joachim Peitz, Gerd Horneff Pediatric Rheumatology Centre, Department of General Pediatrics and Neon...
We have evaluated drug retention rate and predictive factors of drug survival for interleukin-1 inhi...
Systemic juvenile idiopathic arthritis and adult-onset Still's disease are rare autoinflammatory dis...
Abstract Background Subcutaneous anakinra is an interleukin-1 inhibitor used to treat juvenile idiop...
Pharmacokinetic properties and safety profile of a drug are likely influenced by the disease state o...
Anakinra is a biologic response modifier that competitively antagonises the biologic effects of inte...
The use of NSAIDs for arthritis differs in children from adults in their indications, uses and pharm...
International audienceBACKGROUND: Anakinra pharmacokinetics and pharmacodynamics were investigated i...
Anakinra pharmacokinetics and pharmacodynamics were investigated in children and adolescents treated...
We have evaluated anakinra drug retention rate and predictive factors of drug survival in a cohort o...
To assess the efficacy of the interleukin 1 receptor antagonist anakinra in systemic-onset juvenile ...
Interleukin 1 (IL-1), a central mediator of innate immunity, is considered a master cytokine of loca...
The pharmacokinetics and pharmacodynamic (PD) properties of a monoclonal antibody, canakinumab, in p...
Objectives To assess the effi cacy of the interleukin 1 receptor antagonist anakinra in systemic-ons...
Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idio...
Joachim Peitz, Gerd Horneff Pediatric Rheumatology Centre, Department of General Pediatrics and Neon...
We have evaluated drug retention rate and predictive factors of drug survival for interleukin-1 inhi...
Systemic juvenile idiopathic arthritis and adult-onset Still's disease are rare autoinflammatory dis...
Abstract Background Subcutaneous anakinra is an interleukin-1 inhibitor used to treat juvenile idiop...
Pharmacokinetic properties and safety profile of a drug are likely influenced by the disease state o...
Anakinra is a biologic response modifier that competitively antagonises the biologic effects of inte...
The use of NSAIDs for arthritis differs in children from adults in their indications, uses and pharm...